Prevalence of Interactions between Dietary Supplements and Oncologic pharmacotherapy in patients with solid tumours

Prevalence of Interactions between Dietary Supplements and Oncologic pharmacotherapy in patients with solid tumours - PIDSO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031264

Enrollment

107

Registered

2023-02-28

Start date

2023-02-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with solid tumours

Interventions

Group 1: Patients with solid tumours. The occurrence of potential interactions between dietary supplements and oncological pharmacotherapies is being investigated.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of a solid tumour outpatient or inpatient oncologic pharmacotherapy

Exclusion criteria

Exclusion criteria: Dementia comorbidities Expected life expectancy of < 6 months

Design outcomes

Primary

Measure	Time frame
Prevalence of interactions between dietary supplements and oncological pharmacotherapy (in percent) at the time of oncological therapy	—

Secondary

Measure	Time frame
- Prevalence of interactions between dietary supplements (DS) and oncological pharmacotherapy in DS users - Frequency of need for medical intervention due to detected interactions - Prevalence of interactions between DS and the complete (also non-oncological) medication - Influence of other variables on the occurrence of interactions between DS and oncological pharmacotherapy as well as the complete medication (Age, sex, tumour entity, comorbidities, total number of drugs taken, type and total number of DS taken) - Patients‘ quality of life (using EORTC QLQ-C30 Version 3.0) - Motivation for taking DS	—

Measure

Time frame

- Prevalence of interactions between dietary supplements (DS) and oncological pharmacotherapy in DS users - Frequency of need for medical intervention due to detected interactions - Prevalence of interactions between DS and the complete (also non-oncological) medication - Influence of other variables on the occurrence of interactions between DS and oncological pharmacotherapy as well as the complete medication (Age, sex, tumour entity, comorbidities, total number of drugs taken, type and total number of DS taken) - Patients‘ quality of life (using EORTC QLQ-C30 Version 3.0) - Motivation for taking DS

—

Countries

Germany

Contacts

Public ContactMartin Smollich

Institut für Ernährungsmedizin, Universität zu Lübeck

martin.smollich@uksh.de+ 49 (0) 451 3101-8401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026